Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.
暂无分享,去创建一个
W. Shafer | Hong Wu | A. Jerse | A. Kunz | Afrina Begum | Jonathan D'Ambrozio | M. Bash | James M. Robinson
[1] M. Unemo,et al. Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone , 2011, Antimicrobial Agents and Chemotherapy.
[2] Hong Wu,et al. Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections , 2011, Front. Microbio..
[3] Stuart Berman,et al. Sexually transmitted diseases treatment guidelines, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[4] Vanessa G. Allen,et al. Molecular Analysis of Antimicrobial Resistance Mechanisms in Neisseria gonorrhoeae Isolates from Ontario, Canada , 2010, Antimicrobial Agents and Chemotherapy.
[5] Sebastian Bonhoeffer,et al. Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations , 2010, Antimicrobial Agents and Chemotherapy.
[6] S. Porwollik,et al. Fitness Costs and Stability of a High-Level Ciprofloxacin Resistance Phenotype in Salmonella enterica Serotype Enteritidis: Reduced Infectivity Associated with Decreased Expression of Salmonella Pathogenicity Island 1 Genes , 2009, Antimicrobial Agents and Chemotherapy.
[7] D. Hughes,et al. Interplay in the Selection of Fluoroquinolone Resistance and Bacterial Fitness , 2009, PLoS pathogens.
[8] A. Jerse,et al. Local and humoral immune responses against primary and repeat Neisseria gonorrhoeae genital tract infections of 17beta-estradiol-treated mice. , 2008, Vaccine.
[9] Douglas M. Warner,et al. Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC‐MtrD‐MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness , 2008, Molecular microbiology.
[10] Yanpeng Ding,et al. NorB, an Efflux Pump in Staphylococcus aureus Strain MW2, Contributes to Bacterial Fitness in Abscesses , 2008, Journal of bacteriology.
[11] S. Gillespie,et al. Fluoroquinolone-Resistant Mutants of Burkholderia cepacia , 2007, Antimicrobial Agents and Chemotherapy.
[12] Douglas M. Warner,et al. Regulation of the MtrC-MtrD-MtrE efflux-pump system modulates the in vivo fitness of Neisseria gonorrhoeae. , 2007, The Journal of infectious diseases.
[13] Anna A. Vickers,et al. Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies. , 2007, The Journal of antimicrobial chemotherapy.
[14] B. Levin,et al. Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae , 2006, Antimicrobial Agents and Chemotherapy.
[15] D. Andersson. The biological cost of mutational antibiotic resistance: any practical conclusions? , 2006, Current opinion in microbiology.
[16] Lei Wu,et al. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. , 2006, The Journal of antimicrobial chemotherapy.
[17] K. Workowski,et al. Sexually transmitted diseases treatment guidelines, 2006. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[18] Hong Wu,et al. α-2,3-Sialyltransferase Enhances Neisseria gonorrhoeae Survival during Experimental Murine Genital Tract Infection , 2006, Infection and Immunity.
[19] P. McDermott,et al. Fitness of antimicrobial-resistant Campylobacter and Salmonella. , 2006, Microbes and infection.
[20] M. Lipsitch,et al. Incremental increase in fitness cost with increased beta -lactam resistance in pneumococci evaluated by competition in an infant rat nasal colonization model. , 2006, The Journal of infectious diseases.
[21] John W Tapsall,et al. Antibiotic resistance in Neisseria gonorrhoeae. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] D. Sandvang,et al. Biological Cost of Single and Multiple Norfloxacin Resistance Mutations in Escherichia coli Implicated in Urinary Tract Infections , 2005, Antimicrobial Agents and Chemotherapy.
[23] O. Sahin,et al. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[24] H. Hayashi,et al. High Occurrence of Simultaneous Mutations in Target Enzymes and MtrRCDE Efflux System in Quinolone-Resistant Neisseria gonorrhoeae , 2004, Sexually transmitted diseases.
[25] J. Yuenger,et al. Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies. , 2004, The Journal of infectious diseases.
[26] S. Eriksson,et al. Fusidic Acid-Resistant Mutants of Salmonella enterica Serovar Typhimurium with Low Fitness In Vivo Are Defective in RpoS Induction , 2003, Antimicrobial Agents and Chemotherapy.
[27] Lori A. S. Snyder,et al. A Gonococcal Efflux Pump System Enhances Bacterial Survival in a Female Mouse Model of Genital Tract Infection , 2003, Infection and Immunity.
[28] Gale R. Burstein,et al. Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.
[29] F. Tubau,et al. Viridans Group Streptococci Are Donors in Horizontal Transfer of Topoisomerase IV Genes to Streptococcus pneumoniae , 2003, Antimicrobial Agents and Chemotherapy.
[30] H. Lo,et al. Molecular mechanisms of fluoroquinolone resistance. , 2003, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[31] O. Berg,et al. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[32] J. Ruiz,et al. Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. , 2001, The Journal of antimicrobial chemotherapy.
[33] D. Trees,et al. Molecular Epidemiology of Neisseria gonorrhoeae Exhibiting Decreased Susceptibility and Resistance to Ciprofloxacin in Hawaii, 1991–1999 , 2001, Sexually transmitted diseases.
[34] D. Andersson,et al. Biological cost and compensatory evolution in fusidic acid‐resistant Staphylococcus aureus , 2001, Molecular microbiology.
[35] A. Jerse. Experimental Gonococcal Genital Tract Infection and Opacity Protein Expression in Estradiol-Treated Mice , 1999, Infection and Immunity.
[36] W. Whittington,et al. Alterations within the quinolone resistance-determining regions of GyrA and ParC of Neisseria gonorrhoeae isolated in the Far East and the United States. , 1999, International journal of antimicrobial agents.
[37] D. Fleming,et al. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. , 1999, Sexually transmitted infections.
[38] W. Shafer,et al. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. Yasuda,et al. Fluoroquinolone Treatment Failure in Gonorrhea: Emergence of a Neisseria gonorrhoeae Strain With Enhanced Resistance to Fluoroquinolones , 1997, Sexually transmitted diseases.
[40] D. Stein,et al. Use of a non-selective transformation technique to construct a multiply restriction/modification-deficient mutant ofNeisseria gonorrhoeae , 1996, Molecular and General Genetics MGG.
[41] W. Whittington,et al. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin , 1995, Antimicrobial agents and chemotherapy.
[42] W. Shafer,et al. Transcriptional control of the mtr efflux system of Neisseria gonorrhoeae , 1995, Journal of bacteriology.
[43] B. Spratt,et al. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. , 1995, Microbiology.
[44] W. M. Huang,et al. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone‐resistant isolates , 1994, Molecular microbiology.
[45] K. Workowski,et al. Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] I. Kobayashi,et al. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. , 2006, International journal of antimicrobial agents.
[47] Hong Wu,et al. Alpha-2,3-sialyltransferase enhances Neisseria gonorrhoeae survival during experimental murine genital tract infection. , 2006, Infection and immunity.